First slide
Sureseq Logo

Product summary

  • Technology NGS
  • Application Haematology
  • Areas of interest MPN, Myeloid
  • Panel Size 1 Kb
  • Gene Targets 3
  • Aberration Types SNV, indel, translocation (optional)
  • DNA input recommended >500ng high quality DNA
  • Limit of detection SNVs / indels: 1% VAF
  • Workflow 30 minutes hybridisation, 1-day sample-to-sequencer
  • Product Code 770001-24
  • Regulatory Status For research use only; not for diagnostic procedures.



Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases characterised by the overproduction of one or more types of blood cells. The SureSeq™ Core MPN Panel has been designed in collaboration with recognised cancer experts to detect somatic variants in 3 clinically relevant MPN-associated genes; JAK2MPL and CALR (Table 1). The SureSeq Core MPN Panel provides researchers with a single, 1-day NGS workflow for studies into the diagnosis, aetiology and prognosis of MPNs.

  • Unparalleled uniformity and high depth of coverage — detect low frequency SNVs and indels with confidence
  • Time and cost savings — replace multiple single gene assays with a focused NGS panel
  • 1 day from sample to sequencer — streamlined library preparation and rapid 30-minute hybridisation
  • Additional BCR-ABL fusion gene detection — customise your panel by adding BCR-ABL translocation content
  • Complimentary Interpret NGS data analysis software — easy-to-use analysis solution for accurate identification of all variants and translocations

Gene targets

Select a gene to view exon coverage examples:

* Exon examples not yet available


Reliable detection of SNVs, insertions and deletions

The hybridisation-based SureSeq Core MPN Panel is able to consistently detect SNVs and indels down to 1% minor allele frequency (MAF), using a streamlined 1-day workflow. Facilitated by OGT’s expert bait design, the panel delivers the turn-around time of an amplicon-based protocol with the superior coverage uniformity of a hybridisation-based panel, enabling confident detection of key MPN variants including a 52 bp deletion in CALR exon 9 and a 6 bp deletion in JAK2 exon 12 (Figures 1 and 2).

Bespoke panel content including BCR-ABL fusion detection

The BCR-ABL gene fusion is formed following a balanced translocation of chromosome 9 and 22, generating the Philadelphia chromosome. Most MPNs are negative for BCR-ABL, however this translocation is a hallmark of chronic myeloid leukaemia (CML) (Figure 3).

With SureSeq myPanel™, our regularly updated, expert-curated library of pre-optimised cancer content, you can customise your SureSeq Core MPN Panel and add BCR-ABL fusion gene detection, as well as other myeloid content, to create your ideal custom SureSeq myPanel MPN Panel. Combine SNV and indel detection with translocation content and replace multiple assays with a single streamlined NGS workflow for a more comprehensive picture of all your MPN samples.

Complimentary Interpret NGS analysis software

Interpret is OGT’s powerful and easy-to-use data analysis solution, facilitating analysis and visualisation of a wide range of somatic variants and structural aberrations. Designed to work seamlessly with all SureSeq panels, Interpret perfectly complements the SureSeq Core MPN Panel, delivering fast and accurate detection of SNVs and indels, as well as BCR-ABL and other translocation events for customised panels. Following detection, all variants can be readily visualised in the user-friendly variant browser, for an effortless translation of all your MPN data into meaningful results.

SureSeq Core MPN Panel workflow

Content selection Image

Content selection

Sure Seq Bar 1
  • SureSeq Core MPN Panel

Request a quote for this product

View all products

NGS resources & support